Allogeneic NKX101 in liver cancer

Simon Ng — Tue, 26 Oct 2021 09:52:59 +0000

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, discusses NKX101 in solid tumor indications. NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, is currently being assessed in patients with relapsed/refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) in a Phase I trial (NCT04623944). In addition to AML and MDS, NKX101 use is being extended to liver localized tumors including hepatocellular carcinoma (HCC) and metastatic colorectal cancer. Transarterial delivery will enable successful trafficking of the cell therapy to the tumor by concentrating NKX101 in the tumor. This interview took place at Meeting on the Mesa 2021.

CT053, anti-GPC3 CAR-T and targeting solid tumors

admin_vjr_user — Wed, 10 Mar 2021 19:30:20 +0000

Hong Ma, MD, MSc, MBA, CARsgen Therapeutics, Shanghai, China, provides an overview of recent data obtained from a number of Phase I clinical trials evaluating CT053, a fully human B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma. Studies discussed include LUMMICAR-1 (NCT03975907), LUMMICAR-2 (NCT03915184) and an investigator-initiated program in eastern China (NCT03716856, NCT03302403 and NCT03380039). In addition, Dr Ma describes recent and ongoing studies evaluating anti-GPC3 CAR-T cell therapy in patients with hepatocellular carcinoma. He also discusses overcoming the major challenges associated with targeting solid tumors using CAR-T therapies. This interview took place during the CAR-TCR Summit Europe 2021.

Hepatocellular Carcinoma – VJRegenMed

Allogeneic NKX101 in liver cancer

CT053, anti-GPC3 CAR-T and targeting solid tumors